Huiqiang Huang

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

Carlo Gambacorti‐Passerini, Sergey Orlov, Li Zhang et al. · American Journal of Hematology · 2018 · 110 citations · Full text

Medicine, Oncology, Pharmacology +15

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma

Jun Cai, Panpan Liu, Huiqiang Huang et al. · Signal Transduction and Targeted Therapy · 2020 · 83 citations · Full text

Medicine, Hematology, Oncology +17

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Guo‐Wang Lin, Caigang Xu, Kexin Chen et al. · The Lancet Oncology · 2019 · 71 citations

Life Sciences, Genetics, Oncology +17

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Huiqiang Huang, Jun Zhu, Ming Yao et al. · Journal of Hematology & Oncology · 2021 · 61 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Clinical significance of ascites in epithelial ovarian cancer

Huiqiang Huang, Y. J. Li, Chunyan Lan et al. · Neoplasma · 2013 · 60 citations · Full text

Medicine, Oncology, Pathology +16